It has been reported that STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells [52], suggesting that STAT3 represents a promising therapeutic target for the treatment of RCC. This evidence concerns the gene VEGFA and renal carcinoma.